Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized open-label trial of insulin glargine + lixisenatide fixed-ratio combination versus components in type 2 diabetes mellitus
2011-002090-36Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c. Started Oct 2011; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002090-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002090-36.